CONFERENCE REPORT

SCHISTOSOMA 2026

II Global Virtual Symposium on Schistosomiasis

June 2, 2026 Virtual (EDT)
01
ABOUT THE EVENT

II Global Virtual Symposium on Schistosomiasis

SCHISTOSOMA 2026 June 2, 2026 Format: Virtual (EDT) Organized by: Impact Research Communications (IRC)

The 2026 Global Virtual Symposium on Schistosomiasis convened leading parasitologists, immunologists, and clinicians to advance knowledge on schistosome biology, host-parasite interactions, diagnostics, vaccines, and therapeutic strategies. Over a full day of sessions, the symposium showcased breakthroughs in molecular technologies, immune mechanisms, vaccine development, and clinical interventions—underscoring the urgent need for innovation in combating schistosomiasis worldwide.

02
SCIENTIFIC HIGHLIGHTS

Day Highlights

Session I: Molecular Technologies & Diagnostics

  • Dr. Hong You (Australia) presented next-generation molecular tools for enhanced schistosomiasis control.
  • Dr. Fabien Prodjinotho (Germany) highlighted lipid metabolism as a vulnerability in schistosomes.
  • Dr. Joachim Richter (Germany) updated WHO's ultrasound protocol ("Basel protocol") for schistosomiasis.
  • Dr. Carlos Graeff-Teixeira (Brazil) raised concerns about accuracy in diagnostic studies.

Session II: Host-Parasite Interactions & Immunity

  • Dr. Parisa Kalantari (USA) demonstrated how NLRP3 and AIM2 inflammasomes exacerbate Th17 responses to schistosome eggs.
  • Dr. Cecile Crosnier (UK) used a human receptor platform to map extracellular host-parasite protein interactions.
  • Dr. Jayhun Lee (USA) explored host and parasite factors modulating schistosome development and immune evasion.
  • Dr. Thiago De Almeida Pereira (USA) examined fibrosis pathways and therapeutic opportunities.

Session III: Vaccines & Clinical Advances

  • Dr. Jeroen Pollet (USA) reported protective immunity from mRNA vaccines encoding Sm-TSP-2 variants.
  • Dr. Darrick Carter (USA) shared interim clinical trial results for the SchistoShield vaccine.
  • Dr. Miriam Tendler (Brazil) presented progress on the Sm14 FABP vaccine (Schistovac) in Brazil and Africa.
  • Dr. Jennifer Friedman (USA) discussed RCT results on praziquantel treatment in pregnant women.
  • Dr. Susannah Colt (USA) reported RCT findings on praziquantel dosing in preschool-aged children.

The symposium concluded with remarks emphasizing the convergence of molecular innovation, immunology, and clinical research in advancing schistosomiasis management.

03
INTERNATIONAL COLLABORATION

Global Participation

Countries represented included: Australia, Germany, Brazil, UK, USA , and others—reflecting the international scope of schistosomiasis research and collaboration.

04
KEY FINDINGS

Key Takeaways

  • Molecular innovation: Cutting-edge technologies are reshaping diagnostics and control strategies.
  • Host-parasite crosstalk: New insights into immune evasion and pathogenic responses highlight therapeutic targets.
  • Vaccine development: Vaccine platforms, including mRNA, protein-based approaches, and clinical trials, show promising progress.
  • Clinical interventions: Optimized praziquantel use in vulnerable populations is advancing treatment standards.
  • Global collaboration: The symposium reaffirmed the collective commitment to tackling schistosomiasis through interdisciplinary science and innovation.